BSI 050
Alternative Names: BSI-050Latest Information Update: 02 Dec 2021
At a glance
- Originator Biosion
- Class Antibodies; Antineoplastics; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; CD47 antigen inhibitors; SIRPA protein inhibitors; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Solid tumours
Highest Development Phases
- Preclinical Breast cancer; Solid tumours
Most Recent Events
- 02 Dec 2021 Biosion plans a phase I trial in Breast cancer in 2021/2022 (Biosion pipeline, December 2021)
- 29 Nov 2021 Biosion has patent for BSI 050 for discussion under Confidential Disclosure Agreement (CDA) (Biosion website, November 2021)
- 29 Nov 2021 Pharmacodynamics data from a preclinical study in Solid tumours released by Biosion